Cogent Biosciences, Inc. COGT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -73.7%+25.8pp | -99.5%-24.6pp | -74.9%-15.2pp | -59.7%-27.5pp | |
| Return on assets | -52%+27.8pp | -79.8%-17.1pp | -62.6%-10.0pp | -52.6%-22.7pp | |
| Return on invested capital | -129.2%+9.1pp | -138.3%-22.3pp | -116%— | —— | |
| Liquidity | |||||
| Current ratio | 14.2×+8.9× | 5.3×-1.8× | 7.1×-2.8× | 9.9×-3.2× | |
| Quick ratio | 14.2×+8.9× | 5.3×-1.8× | 7.1×-2.8× | 9.9×-3.2× | |
| Cash ratio | 4.9×+3.1× | 1.8×+0.4× | 1.4×-3.8× | 5.2×-7.7× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Debt-to-assets | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | |
| Interest coverage | -108.9×— | —— | —— | —— | |
| Per Share | |||||
| Book value per share | $4.94+100% | $2.47-23.8% | $3.24-25.7% | $4.35-21.3% | |
| Valuation | |||||
| Market capitalization | $5.45B+533% | $861.6M+70.1% | $506.41M-37.3% | $807.97M+136% | |
| Enterprise value | $5.16B+560% | $780.9M+65.4% | $472.03M-31.4% | $687.73M+448% | |
| Price / book | 8.6×+5.2× | 3.4×+1.4× | 2×-1.2× | 3.2×+1.6× | |
| Free cash flow yield | -4.9%+19.3pp | -24.2%+6.7pp | -30.9%-15.4pp | -15.5%— | |
| Earnings yield | -6%+23.7pp | -29.7%+8.3pp | -38%-20.6pp | -17.4%+3.8pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cogent Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cogent Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
